Does MK-677 (ibutamoren) actually work, and is it safe?

The short answer

MK-677, also known as ibutamoren, is an oral compound that mimics ghrelin to reliably raise growth hormone and IGF-1 — and it boosts appetite and, for many, sleep. Human trials show it adds a small amount of lean mass, but that gain didn't improve strength, it worsens insulin sensitivity, and it causes fluid retention. It's popular because it's oral, but it's unapproved and the trade-offs are real.

Evidence tier: Tier 1–2 for the GH/IGF-1 and body-composition effects; Tier 2 for the side-effect profile. Educational content, not medical advice.

The key points:

• Oral ghrelin mimetic — raises GH & IGF-1 without injections (and it's not a peptide)
• Adds lean mass, but not strength — and some of the gain is water
• Worsens insulin sensitivity and causes fluid retention — real downsides
• Unapproved — failed clinical-outcome trials; WADA-banned in sport

For how it compares to the injectable GH peptides, see GH peptides for muscle: the honest evidence.

What is MK-677 (ibutamoren)?

Evidence tier: 1–2 — well-characterized pharmacology.

MK-677 is a selective ghrelin-receptor agonist — it binds the same receptor as your hunger hormone ghrelin and sends a "release growth hormone" signal to the pituitary, raising GH and, downstream, IGF-1. Its two standout practical features are that it's taken orally (no injections, unlike sermorelin, CJC-1295/ipamorelin, or tesamorelin) and that it raises IGF-1 in a sustained way — the effect doesn't fade with continued use (no tachyphylaxis). Alongside the GH effect, it strongly stimulates appetite (same ghrelin pathway) and many users report deeper sleep.

One clarification worth making: despite living in the "peptide" world, MK-677 is not a peptide — it's a small orally-active molecule (ibutamoren mesylate). That's exactly why it works as a pill: peptide GH secretagogues generally have to be injected, while MK-677's small-molecule structure survives oral dosing. That convenience is the main reason it's so popular among people who want the GH/IGF-1 route without needles. The real question isn't whether it raises GH and IGF-1 — it clearly does — but whether that translates into the benefits people are chasing, and at what cost.

Does MK-677 actually work?

Evidence tier: 1 — long-term randomized trial.

For raising IGF-1, yes — and there's good human data. The landmark study is a two-year randomized controlled trial in healthy older adults (the longest controlled MK-677 trial), where 25 mg daily restored IGF-1 to youthful levels and increased fat-free mass by roughly 1 kg, while the placebo group lost lean mass (Nass et al. 2008, *Ann Intern Med*). So the "it builds lean mass" claim has real support: MK-677 reliably increases IGF-1 and adds a modest amount of fat-free mass over time.

But the same trial delivers the crucial caveat: that lean-mass gain did not improve strength or physical function. More fat-free mass on the scale sounds great, but if it doesn't make you stronger or more functional, its value is questionable — and some of the "lean mass" is water, since GH/IGF-1 elevation causes fluid retention (more on that below). So the honest read is that MK-677 does what it says on IGF-1 and body composition numbers, but the functional payoff people imagine — meaningfully stronger, more muscular, more capable — wasn't demonstrated even in a well-run two-year study. It's a real effect on a marker and on lean mass, with an unproven translation to the outcomes that actually matter.

What are the side effects and risks?

Evidence tier: 1–2 — consistent across trials.

This is where MK-677's picture gets genuinely mixed, because its side effects are not trivial. The most important is worsened insulin sensitivity: across Merck's trials and the two-year study, MK-677 consistently raised fasting glucose and reduced insulin sensitivity — an expected consequence of chronically elevated GH/IGF-1 and ghrelin-receptor activation (Nass 2008; Sigalos & Pastuszak 2018, GH-secretagogue review). For anyone with prediabetes, diabetes, or metabolic-syndrome risk, that's a meaningful concern, and it's the single biggest reason to be cautious with long-term use.

The other recognized effects: fluid retention and edema (the same GH-driven mechanism that causes puffy hands and carpal-tunnel symptoms with injectable GH peptides — see GH peptides: numb hands & fluid retention), strong appetite stimulation (a plus when bulking, a real problem when trying to lose fat), lethargy or muscle aches in some users, and a mild cortisol bump. None of these are typically dangerous short-term, but they shape who MK-677 suits. And its safety at the doses and durations people actually use — often for physique goals, not the supervised trial context — is less characterized than the clinical studies suggest.

Why isn't MK-677 approved?

Evidence tier: 1–2 — regulatory and trial history.

Despite decades of study, MK-677 has never been approved as a drug, and that history is informative. It was investigated by Merck for conditions like age-related muscle loss, frailty, and recovery, but the programs didn't succeed — the compound raised IGF-1 and lean mass but failed to deliver the clinical outcomes (like improved strength, function, or recovery) that would justify approval, and the insulin-resistance signal weighed against it. So MK-677 isn't unapproved because it "doesn't work" on GH/IGF-1; it's unapproved because raising those markers didn't reliably produce meaningful clinical benefit, while the metabolic downsides were consistent.

That's a more honest framing than either camp offers. MK-677 boosters point to the real IGF-1 and lean-mass data; critics point to the lack of approval as if it were useless. The accurate middle: it does measurably what it claims biochemically, but the pharma company that studied it most couldn't turn that into an approvable benefit. It's also banned in sport by WADA as a growth-hormone secretagogue. Today it circulates as a gray-market "research" compound, with the usual purity and authenticity uncertainties on top of the pharmacology (spotting counterfeit peptides).

Who might MK-677 suit — and who should avoid it?

Evidence tier: 2 — reasoned from the profile.

MK-677 makes the most sense for a narrow case: someone in a bulking/mass-gain phase who actively wants the appetite stimulation and doesn't mind some water retention, is metabolically healthy, and understands they're chasing IGF-1 and lean-mass numbers rather than a proven strength or health benefit. The oral convenience and the sleep/appetite effects are the genuine draws. Even then, monitoring fasting glucose and being honest that the strength payoff is unproven is the sensible approach.

Who should be cautious or avoid it: anyone with insulin resistance, prediabetes, diabetes, or metabolic-syndrome risk (the glucose effect is the real hazard), anyone in a fat-loss phase (the appetite surge works against you), anyone competing in tested sport (it's banned), and anyone expecting it to be a clean "more muscle and strength" drug — because the best long-term trial specifically didn't show the strength benefit. As always, this is general education, not a recommendation; the metabolic effects in particular are worth discussing with a clinician before considering it.

Limitations

This is educational content, not medical advice.

• Raises IGF-1 and lean mass, but not strength — the functional benefit is unproven even in a 2-year trial.
• Worsens insulin sensitivity / raises fasting glucose — a real concern, especially with metabolic risk or long-term use.
• Causes fluid retention — some "lean mass" is water; GH-type edema effects apply.
• Never approved — failed to deliver approvable clinical outcomes; WADA-banned.
• It's a small molecule, not a peptide, and gray-market supply adds purity/authenticity risk.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

MK-677 (ibutamoren) does the biochemistry it promises: an oral ghrelin mimetic that reliably raises GH and IGF-1, stimulates appetite, often improves sleep, and adds a modest amount of lean mass over time. But the honest picture is mixed — the best long-term trial showed the lean-mass gain didn't translate into strength, some of the gain is water, and it consistently worsens insulin sensitivity and causes fluid retention. It's never been approved because raising IGF-1 didn't produce approvable clinical benefits, and it's banned in sport. It's a reasonable, convenient option for a metabolically healthy person in a mass-gain phase who wants the appetite and IGF-1 effects with eyes open — and a poor choice for anyone with metabolic risk, anyone cutting, or anyone expecting proven strength gains.

Related on this site

• GH peptides for muscle: the honest evidence
• CJC-1295 / ipamorelin stack guide
• GH peptides: numb hands, swelling & fluid retention
• Peptides for muscle growth & body recomposition
• Spotting counterfeit peptides
• Our evidence-tier framework

References

• Nass R, et al. 2008. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 149(9):601–611. PMID 18981485 — 2-year MK-677 trial: IGF-1, lean mass, insulin sensitivity.
• Murphy MG, et al. 1998. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 83(2):320–325. PMID 9467536 — MK-677 pharmacology.
• Sigalos JT, Pastuszak AW. 2018. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. PMID 28330835 — GH-secretagogue class, including metabolic effects.